Endicott M: Principles of treatment for osteosarcoma. Clin Tech Small Anim Pract. 2003, 18: 110-114. 10.1053/svms.2003.36626.
Article
PubMed
Google Scholar
Mirabello L, Troisi RJ, Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009, 115 (7): 1531-1543. 10.1002/cncr.24121.
Article
PubMed Central
PubMed
Google Scholar
Mueller F, Fuchs B, Kaser-Hotz B: Comparative Biology of Human and Canine Osteosarcoma. Anticancer Res. 2007, 27: 155-164.
CAS
PubMed
Google Scholar
De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Levine RA, Buracco P, Di Renzo MF: Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol. 2009, 218: 399-408. 10.1002/path.2549.
Article
CAS
PubMed
Google Scholar
Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA: Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer. 2009, 9: 81-10.1186/1471-2407-9-81.
Article
PubMed Central
PubMed
Google Scholar
Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, Jubala CM, Getzy DM, Cutter GR, Modiano JF, Breen M: Influence of genetic background on tumor karyotypes: evidence for breed–asscoiated aberrations in canine appendicular osteosarcoma. Chromosome Res. 2009, 17: 365-377. 10.1007/s10577-009-9028-z.
Article
PubMed Central
CAS
PubMed
Google Scholar
Morello E, Martano M, Buracco P: Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma. Vet J. 2011, 189 (3): 268-277. 10.1016/j.tvjl.2010.08.014.
Article
PubMed
Google Scholar
Withrow SJ, Wilkins RM: Cross talk from pets to people: translational osteosarcoma treatments. ILAR J. 2010, 51 (3): 208-213.
Article
CAS
PubMed
Google Scholar
MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R: IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem. 2004, 92 (1): 77-91. 10.1002/jcb.20046.
Article
CAS
PubMed
Google Scholar
Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH: Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol. 2004, 41 (3): 291-296. 10.1354/vp.41-3-291.
Article
CAS
PubMed
Google Scholar
Mullins MN, Lana SE, Dernell WS, Ogilvie GK, Withrow SJ, Ehrhart EJ: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med. 2004, 18 (6): 859-865. 10.1111/j.1939-1676.2004.tb02633.x.
Article
PubMed
Google Scholar
Kow K, Thamm DH, Terry J, Grunerud K, Bailey SM, Withrow SJ, Lana SE: Impact of telomerase status on canine osteosarcoma patients. J Vet Intern Med. 2008, 22 (6): 1366-1372. 10.1111/j.1939-1676.2008.0175.x.
Article
CAS
PubMed
Google Scholar
Kirpensteijn J, Kik M, Teske E, Rutteman GR: TP53 gene mutations in canine osteosarcoma. Vet Surg. 2008, 37 (5): 454-460. 10.1111/j.1532-950X.2008.00407.x.
Article
PubMed
Google Scholar
Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol JA: Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer. 2009, 8: 72-10.1186/1476-4598-8-72.
Article
PubMed Central
PubMed
Google Scholar
Selvarajah GT, Kirpensteijn J: Prognostic and predictive biomarkers of canine osteosarcoma. Vet J. 2010, 185 (1): 28-35. 10.1016/j.tvjl.2010.04.010.
Article
CAS
PubMed
Google Scholar
O'Donoghue LE, Ptitsyn AA, Kamstock DA, Siebert J, Thomas RS, Duval DL: Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. BMC Cancer. 2010, 10: 506-10.1186/1471-2407-10-506.
Article
PubMed Central
PubMed
Google Scholar
Sharili AS, Allen S, Smith K, Hargreaves J, Price J, McGonnell I: Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy. Tumour Biol. 2011, 32 (3): 515-526. 10.1007/s13277-010-0146-1.
Article
PubMed Central
CAS
PubMed
Google Scholar
Romanucci M, D’Amato G, Malatesta D, Bongiovanni L, Palmieri C, Ciccarelli A, Buracco P, Morello E, Maniscalco L, De Maria R, Martano M, Della Salda L: Heat shock protein expression in canine osteosarcoma. Cell Stress Chaperones. 2012, 17 (1)): 131-138.
Article
PubMed Central
CAS
PubMed
Google Scholar
Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG, He TC: Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 2002, 102 (4): 338-342. 10.1002/ijc.10719.
Article
PubMed Central
CAS
PubMed
Google Scholar
Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukay K: Cytoplasmatic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis. 2003, 20: 525-529. 10.1023/A:1025821229013.
Article
CAS
PubMed
Google Scholar
Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, Imamura T, Ishikawa Y, Ishida T, Mori S, Machinami R, Kudo A: Anomalous cadherin expression in osteosarcoma, Possible relationships to metastasis and morphogenesis. Am J Pathol. 1999, 155 (5): 1549-1555. 10.1016/S0002-9440(10)65471-5.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, Kudo A, Fukayama M, Grigoriadis AE: Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer. 2003, 104: 147-154. 10.1002/ijc.10931.
Article
CAS
PubMed
Google Scholar
Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A: Wnt 10 b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer. 2008, 51: 349-355. 10.1002/pbc.21595.
Article
CAS
PubMed
Google Scholar
Clenton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PC: Profiling 78 of high grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. Br J Cancer. 2009, 101: 1909-1918. 10.1038/sj.bjc.6605405.
Article
Google Scholar
Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL: Antitumor activity of natural compounds, curcumin and PKF 118–310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs. 2010, 28 (6): 766-782. 10.1007/s10637-009-9311-z.
Article
CAS
PubMed
Google Scholar
Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010, 220 (1): 24-33. 10.1002/path.2628.
Article
CAS
PubMed
Google Scholar
Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R: Expression of LDL-receptors-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer. 2004, 109: 106-111. 10.1002/ijc.11677.
Article
CAS
PubMed
Google Scholar
Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas MD: Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted distruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009, 119: 837-851. 10.1172/JCI37175.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhang F, Chen A, Chen J, Yu T, Guo F: Influence of β-catenin small interfering RNA on human osteosarcoma cells. J Huazhong Univ Sci Technolog Med Sci. 2011, 31 (3): 353-358. 10.1007/s11596-011-0380-9.
Article
CAS
PubMed
Google Scholar
Trieb K, Lehner R, Stulnig R, Sulzbacher I, Shoryer KR: Survivin expression in human osteosarcoma is amarker for survivalEur. J Surg Oncol. 2003, 29: 379-382. 10.1053/ejso.2002.1415.
Article
CAS
Google Scholar
Wang W, Huiying L, Wang A: Expression of Survivin and correlation with PCNA in Osteosarcoma. J Surg Oncol. 2006, 93: 578-584. 10.1002/jso.20507.
Article
CAS
PubMed
Google Scholar
Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J: Survivin as a prognostic factor for osteosarcoma patients. JSHC. 2006, 39 (3): 95-100.
CAS
Google Scholar
Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J: Survivin expression levels as Indipendent predictors of survival for osteosarcoma patients. J Orthop Res. 2007, 25 (1): 116-121. 10.1002/jor.20291.
Article
CAS
PubMed
Google Scholar
Clark JC, Dass CR, Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008, 134 (3): 281-297. 10.1007/s00432-007-0330-x.
Article
CAS
PubMed
Google Scholar
Do SI, Jung WW, Kim HS, Park Y: The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Inter Journal of oncol. 2009, 34: 797-803.
CAS
Google Scholar
Shoeneman JK, Ehrhart EJ, Eickhoff JC, Charles JB, Powers BE, Thamm DH: Expression and function of survivin in canine osteosarcoma. Cancer Res. 2012, 72 (1)): 249-259.
Article
CAS
PubMed
Google Scholar
Kanwar JR, Kamalapuram SK, Kanwar RK: Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today. 2011, 16 (11–12): 485-494.
Article
CAS
PubMed
Google Scholar
Guha M, Altieri DC: Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 2009, 8 (17): 2708-2710. 10.4161/cc.8.17.9457.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC: Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003, 362 (9379): 205-209. 10.1016/S0140-6736(03)13910-4.
Article
CAS
PubMed
Google Scholar
Bongiovanni L, Muller EJ, Della Salda L: Survivin in skin pathologies. Exp Dermatol. 2011, 20 (6): 456-463.
Article
Google Scholar
Mendoza S, Conischi T, Dernell WS, Withrow SJ, Miller CW: Status of the p53, Rb and Mdm2 Genes in Canine Osteosarcoma. Anticancer Res. 1998, 18: 4449-4454.
CAS
PubMed
Google Scholar
Chandar N, Saluja R, Lamar PC, Kolman K, Prozialeck WC: P53 and Beta-catenin activity during estrogen treatment of osteoblasts. Cancer Cell International. 2005, 5: 24-10.1186/1475-2867-5-24.
Article
PubMed Central
PubMed
Google Scholar
Damalas A, Kahan S, Shtutman M, Ben-Ze’ev A, Oren M: Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperated with Ras in transformation. EMBO J. 2001, 20 (17): 4912-4922. 10.1093/emboj/20.17.4912.
Article
PubMed Central
CAS
PubMed
Google Scholar
Slayter MV, Boosinger TR, Pool RR, Dammrich K, Misdorp W, Larsen S: Histological classification of bone and joint tumors of domestic animals, Vol.1. 1994, Armed Forces Institute of Pathology, Washington DC, 5-45. 2
Google Scholar
Kirpensteijn J, Kik M, Rutteman GR, Teske E: Prognostic significance of a new histologic grading system for Canine Osteosarcoma. Vet Pathol. 2002, 39 (2): 240-246. 10.1354/vp.39-2-240.
Article
CAS
PubMed
Google Scholar
Day TF, Guo X, Garrett-Beal L, Yang Y: Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005, 8 (5): 739-750. 10.1016/j.devcel.2005.03.016.
Article
CAS
PubMed
Google Scholar
Glass DA, Karsenty G: In vivo analysis of Wnt signaling in bone. Endocrinology. 2007, 148 (6): 2630-2634. 10.1210/en.2006-1372.
Article
CAS
PubMed
Google Scholar
Thomas DM: Wnts, bone and cancer. J Pathol. 2010, 220 (1): 1-4. 10.1002/path.2635.
Article
CAS
PubMed
Google Scholar
Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127 (3): 469-480. 10.1016/j.cell.2006.10.018.
Article
CAS
PubMed
Google Scholar
Fodde R, Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007, 19 (2): 150-158. 10.1016/j.ceb.2007.02.007.
Article
CAS
PubMed
Google Scholar
Stein TJ, Holmes KE, Muthuswamy A, Thompson V, Huelsmeyer MK: Characterization of β-catenin expression in canine osteosarcoma. Vet Comp Oncol. 2011, 9 (1): 65-73. 10.1111/j.1476-5829.2010.00236.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Piskun CM, Muthuswamy A, Huelsmeyer MK, Thompson V, Stein TJ: Wnt/β-catenin expression does not correlate with serum alkaline phosphatase concentration in canine osteosarcoma patients. PLoS One. 2011, 6 (10): e26106-10.1371/journal.pone.0026106.
Article
PubMed Central
CAS
PubMed
Google Scholar
Garzotto CK, Berg J, Hoffmann WE, Rand WM: Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Int Med. 2000, 14: 587-592. 10.1111/j.1939-1676.2000.tb02281.x.
Article
CAS
Google Scholar
Behrens J, Lustig B: The Wnt connection to tumorigenesis. Int J Dev Biol. 2004, 48: 477-487. 10.1387/ijdb.041815jb.
Article
CAS
PubMed
Google Scholar
Verkaar F, van der Stelt M, Blankesteijn WM, van der Doelen AA, Zaman GJ: Discovery of novel small molecule activators of β-catenin signaling. PLoS One. 2011, 6 (4): e19185-10.1371/journal.pone.0019185.
Article
PubMed Central
CAS
PubMed
Google Scholar
Stauber RH, Mann W, Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007, 67 (13): 5999-6002. 10.1158/0008-5472.CAN-07-0494.
Article
CAS
PubMed
Google Scholar
Caldas H, Honsey LE, Altura RA: Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005, 4: 11-10.1186/1476-4598-4-11.
Article
PubMed Central
PubMed
Google Scholar
Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD: Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999, 59: 6097-6102.
CAS
PubMed
Google Scholar
Su L, Wang Y, Xiao M, Lin Y, Yu L: Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010, 110 (4): 484-491. 10.1016/j.tripleo.2010.04.009.
Article
PubMed
Google Scholar
Lechler P, Renkawitz T, Campean V, Balakrishnan S, Tingart M, Grifka J, Schaumburger J: The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer. 2011, 11: 120-10.1186/1471-2407-11-120.
Article
PubMed Central
CAS
PubMed
Google Scholar
Cheung CH, Cheng L, Chang KY, Chen HH, Chang JY: Investigations of survivin: the past, present and future. Front Biosci. 2011, 16: 952-961. 10.2741/3728.
Article
CAS
Google Scholar
Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA: Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer. 2011, 11: 125-10.1186/1471-2407-11-125.
Article
PubMed Central
CAS
PubMed
Google Scholar
McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA: The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer. 2009, 125 (12): 2792-2801. 10.1002/ijc.24660.
Article
CAS
PubMed
Google Scholar
Van Leeuwen IS, Cornelisse CJ, Misdorp W, Goedegebuure SA, Kirpensteijn J, Rutteman GR: p53 gene mutations in osteosarcoma in the dog. Cancer Lett. 1997, 111: 173-178. 10.1016/S0304-3835(96)04529-6.
Article
CAS
PubMed
Google Scholar
Johnson AS, Couto CG, Weghorst CM: Mutations of p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis. 1998, 19: 213-217. 10.1093/carcin/19.1.213.
Article
CAS
PubMed
Google Scholar
Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP: Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 1990, 50 (24): 7950-7954.
CAS
PubMed
Google Scholar
Tang N, Song WX, Luo J, Haydon RC, He TC: Osteosarcoma and stem cell Differentiation. Clin Orthop Relat Res. 2008, 466: 2114-2130. 10.1007/s11999-008-0335-z.
Article
PubMed Central
PubMed
Google Scholar
Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Werner B, Roessner A: Analysis of mutant p53 protein in osteosarcomas and other malignant and beign lesions of bone. J Cancer Res Clin Oncol. 1993, 119: 172-178. 10.1007/BF01229533.
Article
CAS
PubMed
Google Scholar
Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN: Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010, 150 (2): 237-242. 10.1007/s10517-010-1114-x.
Article
CAS
PubMed
Google Scholar
Sagartz JE, Bodley WL, Gamblin RM, Couto CG, Tierney LA, Capen CC: p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol. 1996, 33: 213-221. 10.1177/030098589603300211.
Article
CAS
PubMed
Google Scholar
Loukopoulos P, Thornthon JR, Robison WF: Clinical and Pathologic Relevance of p53 Index in canine osseus tumors. Vet Pathol. 2003, 40: 237-248. 10.1354/vp.40-3-237.
Article
CAS
PubMed
Google Scholar
Altieri DC: New wirings in the survivin networks. Oncogene. 2008, 27 (48): 6276-6284. 10.1038/onc.2008.303.
Article
PubMed Central
CAS
PubMed
Google Scholar
Buracco P, Martano M, Morello E, Vasconi ME: Pasteurized tumoral autograft as a novel procedure of limb sparing in dogs: a clinical report in a canine distal radial osteosarcoma. Vet Surg. 2002, 31 (6): 525-532. 10.1053/jvet.2002.34674.
Article
PubMed
Google Scholar
Morello E, Vasconi E, Martano M, Peirone B, Buracco P: Pasteurized Tumoral Autograft and Adjuvant Chemotherapy for the Treatment of Canine Distal Radial Osteosarcoma: 13 cases. Vet Surg. 2003, 32 (6): 539-544. 10.1111/j.1532-950X.2003.00539.x.
Article
PubMed
Google Scholar
Dernell WS, Ehrhart NP, Straw RC, Vail DM: Tumors of the skeletal system. Withrow & MacEwen’s Small animal clinical oncology. Edited by: Withrow SJ, Vail DM, Saunders . 2007, Elsevier, St Louis, Missouri, 540-582. 4
Chapter
Google Scholar
Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vail DM, Morrison WB, McGee M, Dickinson : Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med. 1991, 5: 205-210. 10.1111/j.1939-1676.1991.tb00950.x.
Article
CAS
PubMed
Google Scholar
Berg J, Weinstein MJ, Springfield DS, Rand WM: Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc. 1995, 206: 1555-1560.
CAS
PubMed
Google Scholar
Chun R, Garrett LD, Henry C, Wall M, Smith A, Azene NM: Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc. 2005, 41: 382-387.
Article
PubMed
Google Scholar
Bongiovanni L, Colombi I, Fortunato C, Della Salda L: Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas. Vet Dermatol. 2009, 20 (5–6): 369-376.
Article
PubMed
Google Scholar
Bongiovanni L, Malatesta D, Brachelente C, D’Egidio S, Della Salda L: β-Catenin In Canine Skin: Immunohistochemical Pattern Of Expression In Normal Skin And Cutaneous Epithelial Tumors. J Comp Pathol. 2011, 145 (2–3): 138-147.
Article
CAS
PubMed
Google Scholar
Bongiovanni L, Romanucci M, Fant P, Lagadic M, Della Salda L: Apoptosis and anti-apoptotic heat shock proteins in canine cutaneous infundibular keratinizing acanthomas and squamous cell carcinomas. Vet Dermatol. 2008, 19 (5): 271-279. 10.1111/j.1365-3164.2008.00687.x.
Article
PubMed
Google Scholar